You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
晶泰科技傳已祕密赴美申請上市
uSMART盈立智投 08-05 19:11

據路透旗下IFR報道指,騰訊 (00700) 、軟銀等有份投資的藥物研發公司晶泰科技(XtalPi)已經祕密赴美遞交上市申請,早前曾有報道指,公司計劃集資4億至5億美元。

晶泰科技是以計算驅動創新的藥物研發公司,公司的ID4(Intelligent Digital Drug Discovery and Development)智能藥物研發平臺,結合量子物理、人工智能與雲計算技術,可以準確預測小分子藥物的多種重要特性,加速藥物臨牀前研究的效率和成功率。

據資料顯示,騰訊由2015年起已經有參與晶泰科技的A輪融資,2018年及2020年亦分別參投B輪及C輪融資。晶泰科技最新一輪融資,涉及投資金額達3.188億美元,除騰訊外,軟銀、紅杉資本、中金及中信等均有投資。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account